Technique

  1. NON INVASIVE-(NO INCISON, No SUTURE)
  2. DAY CARE
  3. PAINLESS
  4. SAFE – NO SIDE EFFECTS
  5. PATIENT CAN RESUME ACTIVITIES OF DAILY LIVING FROM NEXT DAY

Dose /RouteResult: Results depend on quantity and quality

Quantity: The success rate depends on the amount of cells injected and the quality of cells Ideal is-2-4 million mononuclear cells per kg body weight

Quality is maintained by adhering to Good protocol

Stem cells are infused/injected weekly /fortnightly/monthly as per Different protocols. Total of 3-5 such infusions are suggested.

Route of administration—

Optic atrophy and retinal diseases – Patients suffering from retinal and optic neuropathology may be benefited by a retro bulbar/ injection. The dose /quality and route is decided depending on the patient’s condition

  1. Retrobulbar- for optic atrophy
  2. subscleral/intravitreal— for retinal diseases
  3. intrathecal – neurological disorders
  4. Intravenous /intrarterial
  5. intrarticular
  6. intralesional (direct)

.BASIC PRINCILPLE

We follow both major lines of processing which have emerged –

  • One advocating stem cell enrichment
  • And the other doing expansion with or without differentiating these endogenous stem cells.

Enrichment has the advantage of fresh cells along with cocktail of numerous different types of supportive cells and growth factors neseccary for stem cells to home at lesion and their growth.

Expansion /Culture of stem cells increases the number significantly so as to reach desired number of cells for a therapeutic effect.

Enrichment :

  1. minimal manipulation by any chemical, physical or biologic agent    as these cells are highly sensitive towards process would loosen their properties soon.
  2. Fresh i.e. less time delay between extraction –isolation and enrichment
  3. Provides    cocktail of different fresh stem cells in their natural environment along with numerous different type of supportive cells and growth factors
  4. Good recovery   not only Mesenchymal cells but also Very small embryonic-like stem cells (VSELs) which are the pluripotent stem cells with maximum regenerative potential.
  5. Cells dont  leave there biological environment
  6. Ficoll ” not used as it s biological  effects on cells aging, damage to the genome (genotoxic ), changes in chromatin structure are still inconclusive  . Possibility of mutations and late tumour formation

Expansion:

Stem cells from patient’s own fat /bone marrow/dental pulp/olfactory tissue umbilical cord tissue are grown in serum free media.

Passages only up to 3 times

The karyotyping of the alternate passage of cells showed a normal chromosomal pattern concluding their positive clinical usage.

Cells are then analyzed for viability and tested for stem cell specific characteristic surface markers and for bacterial, fungal and mycoplasmic burden in addition to the endotoxicity measurement.

We prefer to inject these grown cells to Patient as fresh (directly from lab) without cryofreezing them. As extreme cold temperature effects efficacy and thawing reduces viability

Bioactivation — stem cells (either expanded or enriched) are bio activated with laser energy directed on them.

Source of stem cells used by us- We use any one or combination of following.

  1. Patients own Bone marrow derived    MNC & vsels Cultured Msc
  2. Patients own Adipose tissue derived Stromal cells Cultured Msc
  3. lab grown -Cord tissue Derived cultured Mscs

 Bone marrow extraction –

Approx 120 to 240 ml is harvested from iliac crest  at one time.

Aspirate one iliac crest on day 1, second iliac crest on day 15/ and repeat the first iliac crest on day 30. Alternatively we can store the aspirate of Day 1 for future usages so that repeat aspirations are avoided.

 Bone marrow is processed in a closed system for   volume reduction. Approx 40-60 ml of the bone marrow is taken into the lab for expansion

Volume reduced sample is processed to  have rich 2-5 ml of fraction of mnc  (haemopoetic stem cells  and mesenchymal stem cells and endothelial progenitor cells) and adjoining supernatant plasma which is rich in platelets and growth factors .

The typical yield pr 60 ml of bone marrow sample

The concentrate on an average contains 320-380 MIILION MNC, 15 to 18 million Cd 34+ve 10, 0000 to 15, 00000 MSC’s.

 The sample is further processed to recover lost VSELS. This protocol is patent pending.

 The Final volume is brought to 2to 20 ml depending on route of administration.

Support therapy:

Ayurevda

HBo2

Vitamin B1 and Vitamin B12, Vit B3 nicotinic acid

Inj Adenosine triphosphate

Vasodila­tors by oral route